96 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
14 May 24
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results
5:00pm
-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. It is expected to enroll about 50 … ASPIRE (NCT06011798) can be found here.]
Recent and Upcoming Milestones
UBX1325 24-week safety and efficacy data from the Phase 2b ASPIRE DME study
8-K
EX-99.1
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. It is expected to enroll about 50 subjects, with 16-week data … to long-lasting, disease-modifying intervention for DME
UBX1325 16-week safety and efficacy data from the Phase 2b ASPIRE DME study expected
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
(foselutoclax) or any future product candidates;
our expectations regarding the potential benefits, activity, effectiveness, and safety of our drug candidates
8-K
EX-99.1
vz3vh 38q20pl0s
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
guv7o
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
EX-99.1
6yx5cw 8njdn
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
zmut9
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.2
cqsy3f vxknre
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
96mkstone9jgcnla6hq
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
EX-99.1
oh1r90xteknvabycyix
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.2
jv1 6ar8h07ad
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
k5iuxrfxv
25 Oct 22
Prospectus supplement for primary offering
9:39pm